Genprex, which is developing gene therapies for cancer, set the price for its upcoming IPO at $5.00. The company plans to offer a minimum of 2.0 million shares and a maximum of 4.5 million shares. At the midpoint, Genprex would raise $17.5 million at a basic market cap of $76 million. The company plans to list on the Nasdaq under the symbol GNPX. Network 1 Financial Securities acted as lead manager on the deal. The offering is expected to close in early November.
Note: The offering is being made on a min-max "best efforts" basis, and will therefore be excluded from Renaissance's IPO stats.
